中國生物製藥(01177.HK)擬不超9.51億美元購買禮新醫藥95.09%股權
格隆匯7月15日丨中國生物製藥(01177.HK)公告,於2025年7月15日,公司(透過買方)全資收購禮新醫藥,與賣方、禮新醫藥及Ying Qin Zang訂立買賣協議,據此,買方已同意按對價購買而賣方已同意按對價出售禮新醫藥95.09%股權。於本公告日期,買方持有禮新醫藥4.91%股權。於交割後,禮新醫藥將成爲公司間接全資附屬公司。
對價不超過950.92百萬美元。剔除禮新醫藥集團於交割日的估計現金及銀行存款約450百萬美元,買方就收購事項待作出的付款淨額約爲500.9百萬美元。
禮新醫藥爲於中國註冊成立的生物製藥有限公司。禮新醫藥聚焦於腫瘤免疫及腫瘤微環境領域內尚未滿足的治療需求,並基於其自主研發的GPCR及多次跨膜蛋白抗體發現平臺,致力於具有「全球首創」及「同類最佳」發展潛力的生物創新藥研發。
禮新醫藥是一家聚焦腫瘤免疫及腫瘤微環境領域的、全球頂尖的創新藥研發公司,與集團的創新與國際化戰略深度契合。此次收購將顯著增強集團在腫瘤創新領域的核心競爭力和國際影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.